PASIREOTIDE B2305 STUDY GROUP : A 12-month phase 3 study of pasireotide in Cushing’s disease

PASIREOTIDE B2305 STUDY GROUP : A 12-month phase 3 study of pasireotide in Cushing’s disease

• Pasireotide (Signifor™) if FDA approved for the treatment of adults with Cushing’s disease for whom surgery is either not an option or has not been curative.

• Clinicians should monitor the following parameters in patients on pasireotide (Glucose, QT interval, thyroid function, gallstones, and growth hormone deficiency)

Infographic

Reference

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

>